Patent SG-11201408153Y-A (SG)
Title: Prostate-specific membrane antigen antibody drug conjugates
Inventor: BARNETT RICHARD S
IPC: A61K47/48
Filed: 2013-06-07
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/185117 A1 (51) International Patent Classification: A61K 47/48 ( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044850 7 June 2013 (07.06.2013) English English (30) Priority Data: 61/656,883 7 June 2012 (07.06.2012) (71) Applicant: AMBRX, INC. [US/US]; 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (72) Inventors: BARNETT, Richard S.; 306 Belmont Court, San Marcos, CA 92069 (US). TIAN, Feng; 8374 Orange Haven Place, San Diego, CA 92129 (US). PUTNAM, An- na-maria A. Hays; 11522 Cesped Drive, San Diego, CA 92124 (US). GYMNOPOULOS, Marco; 3620 3rd Aven­ ue, San Diego, CA 92103 (DE). KNUDSEN, Nick; 1916 Rohn Road, Escondido, CA 92025 (US). BECK, Andrew; 4732 Kansas Street, Apt. 2, San Diego, CA 92116 (US). SUN, Ying; 14972 Avenida Venusto #65, San Diego, CA 92128 (US). (74) Agent: WALLEN, John W., Ill; 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) l> i-H oo i-H cn i-H o CJ o & (54) Title: PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES (57) Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates com­ prising at least one non-naturally-encoded amino acid. Disclosed herein are aPSMA antibodies with one or more non-naturally en­ coded amino acids and further disclosed are antibody drug conjugates wherein the aPSMA antibodies of the invention are conjug - ated one to or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-trans- lationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dol­ astatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for us­ ing such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin ana­ logs, including therapeutic, diagnostic, and other biotechnology uses.